Healthcare - Press Releases

FORT WORTH, Texas, March 13, 2025 /PRNewswire/ --According toCDC, more than 222 measles cases have been reported across 12 states as of this press release.

As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive, VERZENIO's distinct clinical advantages and ongoing studies could contribute to further market expansion.

SAN FRANCISCO, March 13, 2025 /PRNewswire/ -- Hyde Park Capitalannounced today that its client, Infiniti Medical LLC(and its subsidiary Orthomed UK Ltd), two globally recognized brands specializing in veterinary interventional radiology, cardiology, soft tissue surgery, and orthopedics,has been acquired by Creative Science, a CIMA Animal Healthcompany, and a leader in veterinary medical solutions. CIMA Animal Health, a portfolio company of Incline Equity Partners, is dedicated to improving the lives of animals and those who care for them. Hyde Park Capital, led by Managing Director Craig Lawson, served as the exclusive financial advisor to Infiniti Medical for this transaction.

A case study on how DelveInsight helped a pharma client navigate the evolving metabolic dysfunction-associated steatohepatitis (MASH) landscape with actionable market intelligence

PORTLAND, Ore, March 13, 2025 /PRNewswire/ -- Ann Sacks, an industry leader in luxury tile and stone, is pleased to announce the opening of its latest showroom and slab gallery, Ann Sacks Charlotte, 721 Gov Morrison Street, Unit 110A, Charlotte, NC 28211, phone number (980) 316-3996. The Ann Sacks Showroom and Slab Gallery is open Monday through Friday, 9:00 a.m. to 5:00 p.m., and Saturdays by appointment. Catering to designers and consumers seeking out the finest in home furnishings, South Park was a natural fit for Ann Sacks Charlotte and the range of brands one can experience under its roof.

PLYMOUTH MEETING, Pa., March 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced promising interim results from an ongoing Phase 1 proof-of-concept trial evaluating DMAbs for COVID-19. In the trial, 100% (24/24) of participants who have reached week 72 maintained biologically relevant levels of DMAbs, confirming the durability of in vivo antibody production. Notably, no participant developed anti-drug antibodies (ADA), a common challenge observed in other gene-based delivery platforms, such as adeno-associated virus (AAV) mediated antibody expression. Additionally, the DMAbs were well tolerated, with the most common side effects being mild, temporary injection site reactions, such as pain and redness. The trial is being led by The Wistar Institute in collaboration with INOVIO, AstraZeneca, and clinical investigators at the Perelman School of Medicine at the University of Pennsylvania.

DALLAS, March 13, 2025 /PRNewswire/ --Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in individuals who are blind or losing vision due to various retinal degenerative diseases, today announced that Sulagna Bhattacharya, Chief Executive Officer and Co-Founder of Nanoscope Therapeutics, will present at the H.C. Wainwright 3rd Annual BioConnect Showcase, taking place March 16-18, 2025, on Kiawah Island, SC. Details for the presentation are as follows:

SEATTLE, March 13, 2025 /PRNewswire/ --Washington Poison Center (WAPC), Washington's nonprofit service for free medical advice on poisoning and drug overdoses, is pleased to announce the four winners of its 19th annual Poison Prevention Poster Contest:

SIRUM's pharmacy service, Good Pill Pharmacy, will offer 500+ low-cost medications to anyone in Maryland whose medication costs are too high

RANCHO CUCAMONGA, Calif., March 13, 2025 /PRNewswire/ -- Inland Empire Health Plan (IEHP), the California Community College system and the San Bernardino Community College District (SBCCD) are partnering to connect local college students to low-cost, high-quality health care and CalFresh programs. Known as the Inland Empire Health Plan Equitable Support Demonstration Project, the collaboration is the first of its kind and will serve as a pilot program for other counties across the state.

LINKPING,Sweden, March 14, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra's(STO: SECT B) enterprise imaging module for radiology is ranked number one by users around the world. We also have the most satisfied customers in digital pathology. Our commitment to customer satisfaction is the foundation of our success in all operating areas. The operating profit trend for the Group is positive despite the ongoing transition to service sales. A settlement was also reached in the third quarter regarding Sectra's patented technology for secure communication, which had a positive non-recurring effect on the Group's financial outcomes.

LINKPING,Sweden, March 14, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra's(STO: SECT B) enterprise imaging module for radiology is ranked number one by users around the world. We also have the most satisfied customers in digital pathology. Our commitment to customer satisfaction is the foundation of our success in all operating areas. The operating profit trend for the Group is positive despite the ongoing transition to service sales. A settlement was also reached in the third quarter regarding Sectra's patented technology for secure communication, which had a positive non-recurring effect on the Group's financial outcomes.

NEW YORK and SUZHOU, China, March 14, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, today announced the closing of its $12 million Series B Plus financing. The round was led by Shenzhen Capital Group (SCGC), an existing investor, with participation from Morningside Ventures, also an existing investor, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST).

OSLO, Norway, March 14, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO study" in JU Open Plus this week. The research objective was to assess ifblue light cystoscopy (BLC) aided TURBT has an impact on the clinical outcomes of patients with NMIBC*. Results of the real-world evidence study show that BLC was associated with a statistically significant 38% reduction in risk of recurrence compared to white light cystoscopy (WLC) use alone in a predominantly high-risk NMIBC patient cohort. These results are in line with prior results from multiple randomized controlled clinical trials.

OSLO, Norway, March 14, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO study" in JU Open Plus this week. The research objective was to assess ifblue light cystoscopy (BLC) aided TURBT has an impact on the clinical outcomes of patients with NMIBC*. Results of the real-world evidence study show that BLC was associated with a statistically significant 38% reduction in risk of recurrence compared to white light cystoscopy (WLC) use alone in a predominantly high-risk NMIBC patient cohort. These results are in line with prior results from multiple randomized controlled clinical trials.

American Association of Kidney Patients (AAKP)

SUNNYVALE, Calif., March 13, 2025 /PRNewswire/ --Imagine finishing your last appointment of the day and heading straight home-no staying late for charting, and no missing precious family moments. Dr.Vinni K. Singh envisioned exactly that when she developed DentScribe, the AI-powered dental documentation and patient communication agentic system. Built by a dentist for dentists, DentScribe transforms how dental professionals manage documentation, follow-ups, and patient interactions.

TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader approvals for early-stage treatment all contribute to its promising growth potential.

KING OF PRUSSIA, Pa., March 11, 2025 /PRNewswire/ -- Universal Health Realty Income Trust (NYSE:UHT) announced today that its Board of Trustees voted to pay a dividend of $.735 per share on March 31, 2025 to shareholders of record as of March 24, 2025.

Pilot projects in Maryland, New York, North Carolina, Texas, and Utah to address high rates of food insecurity and diet-related diseases among U.S. Veterans

HONG KONG, March 11, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces encouraging pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies in Australia in healthy subjects with elevated low-density lipoprotein cholesterol (LDL-C) (Part I) and in patients with obesity (Part II) (NCT06427590).

ALEXANDRIA, Va., March 11, 2025 /PRNewswire/ -- Statement Attributable to:Courtney Bugler, CEO, ZERO Prostate Cancer

Top-20-Biopharma nutzt die Veeva Development Cloud, um die Entwicklung von Therapien fr derzeit unheilbare Krankheiten zu beschleunigen

The Ultra low-power BG29 SoC can use a range of different battery compositions to match the energy needs of connected devices. The small size and high-performance of the BG29 SoC is ideal for the demanding needs of small form-factor wearables. (PRNewsfoto/Silicon Labs)

RAICHUR, India, March 12, 2025 /PRNewswire/ --Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug (IND) - Nor Ursodeoxycholic Acid (Nor UDCA) Tablets 500 mg - and recommended marketing authorization for treating non-alcoholic fatty liver disease (NAFLD).